Samuel Bjork
UnclaimedCurrent Firm
Digitalis Ventures
Investments
10+ companies
Focus
Biotech, Digital Health
About Samuel Bjork
Samuel Bjork is a Partner at Digitalis Ventures, the New York firm that creates and invests in early-stage companies solving complex problems in human and animal health. He serves as a board director at Bonum Therapeutics, Elemental Machines, EpiBiologics, Judo Bio, Switch Therapeutics, T-Therapeutics and Terray Therapeutics. He was previously a board director of PetMedix, acquired by Zoetis, and a board observer at Good Therapeutics, acquired by Roche, ScoutBio, acquired by Ceva, SeQure Dx, acquired by MaxCyte, as well as Protego and Nuvig Therapeutics. Before Digitalis, Bjork was a member of the healthcare and clean energy practices at Boston Consulting Group. He earned graduate degrees from Cambridge and Oxford as a Marshall Scholar and an A.B. in chemistry from Harvard University.
Focus Areas
Investment Stage
Notable Investments
Previous Firms
Other Investors at Digitalis Ventures
Investment Profile
Samuel Bjork is a Partner, Digitalis Ventures at Digitalis Ventures, based in Boston, MA.
Samuel's investment focus spans Biotech, Digital Health, AI, Deeptech, primarily investing at the Pre-Seed, Seed, Series A, Series B+ stages. This specialization allows for deep domain knowledge and strong network effects that benefit portfolio companies.
Notable investments include Bonum Therapeutics, Elemental Machines, EpiBiologics, Judo Bio, Switch Therapeutics and 5 other companies. These investments span Biotech and Digital Health.
Before Digitalis Ventures, Samuel worked at Boston Consulting Group. This breadth of experience across multiple firms provides a well-rounded perspective on the venture capital landscape.
Frequently Asked Questions
Who is Samuel Bjork?
Samuel Bjork is a Partner, Digitalis Ventures at Digitalis Ventures, based in Boston, MA. Their investment focus includes Biotech, Digital Health, AI.
What does Samuel Bjork invest in?
Samuel Bjork focuses on investments in Biotech, Digital Health, AI, Deeptech through Digitalis Ventures. These focus areas reflect their domain expertise and the types of startups they actively seek to back.
What are Samuel Bjork's most notable investments?
Samuel Bjork's notable portfolio investments include Bonum Therapeutics, Elemental Machines, EpiBiologics, Judo Bio, Switch Therapeutics. These companies span multiple sectors and stages, reflecting a track record of identifying high-potential startups.
What firm is Samuel Bjork at?
Samuel Bjork is currently at Digitalis Ventures, headquartered in Boston, MA, serving as Partner, Digitalis Ventures. Previously, they worked at Boston Consulting Group.
Fund Operations Resources
Independent guides to the software and workflows venture investors and their firms use to run funds.
Best Fund Administration Software
Independent breakdown of fund administration platforms by fund size.
LP Reporting Software
Tools for capital account statements and investor updates.
Portfolio Monitoring Tools
How GPs track company performance across the portfolio.
VC CRM Software
Deal-flow and relationship management for investors.
Related tools and reading
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.